Overall, the present results suggest that the pharmacological modulation of A3AR represents a novel and appealing therapeutical strategy for the management of inflammatory bowel disorders, as this method is contextually able to dampen the inflammatory process and mitigate the visceral hypersensitivity associated with colitis. The gene discussed is ADORA3; the disease is colitis.